These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 7797598

  • 1. The effect of stem-cell factor, interleukin-3 and erythropoietin on in vitro erythropoiesis in myelodysplastic syndromes.
    Verbeek W, Vehmeyer K, Wörmann B, Hiddemann W.
    J Cancer Res Clin Oncol; 1995; 121(6):338-42. PubMed ID: 7797598
    [Abstract] [Full Text] [Related]

  • 2. Growth analysis of marrow CD34-positive hematopoietic progenitor cells in patients with myelodysplastic syndromes.
    Asano H, Hotta T, Ichihara M, Murate T, Kobayashi M, Saito H.
    Leukemia; 1994 May; 8(5):833-8. PubMed ID: 7514249
    [Abstract] [Full Text] [Related]

  • 3. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis.
    Claessens YE, Bouscary D, Dupont JM, Picard F, Melle J, Gisselbrecht S, Lacombe C, Dreyfus F, Mayeux P, Fontenay-Roupie M.
    Blood; 2002 Mar 01; 99(5):1594-601. PubMed ID: 11861273
    [Abstract] [Full Text] [Related]

  • 4. In vitro stimulation of erythropoiesis by stem cell factor alone in myelodysplastic syndrome patients with elevated endogenous erythropoietin serum levels.
    Zwierzina H, Bammer T, Rollinger-Holzinger I, Herold M, Fenaux P, Nüssler V, Hoflehner E, Geissler D.
    Clin Cancer Res; 1996 Jun 01; 2(6):1031-8. PubMed ID: 9816264
    [Abstract] [Full Text] [Related]

  • 5. Kit ligand improves in vitro erythropoiesis in myelodysplastic syndrome.
    Backx B, Broeders L, Löwenberg B.
    Blood; 1992 Sep 01; 80(5):1213-7. PubMed ID: 1381239
    [Abstract] [Full Text] [Related]

  • 6. CD34+/CD36- cells from myelodysplasia patients have a limited capacity to proliferate but can differentiate in response to Epo and MGF stimulation.
    Brada SJ, de Wolf JT, Hendriks DW, Smit JW, Vellenga E.
    Leukemia; 1998 Jun 01; 12(6):882-6. PubMed ID: 9639415
    [Abstract] [Full Text] [Related]

  • 7. In vitro study of erythropoiesis in patients with aplastic anemia and myelodysplastic syndromes: a possible tool for prospective determination of the clinical effectiveness of growth factors.
    Aoki A, Shibata A.
    Hematol Pathol; 1992 Jun 01; 6(3):143-53. PubMed ID: 1429342
    [Abstract] [Full Text] [Related]

  • 8. In vitro studies of erythropoietin-dependent regulation of erythropoiesis in myelodysplastic syndromes.
    Merchav S, Nielsen OJ, Rosenbaum H, Sharon R, Brenner B, Tatarsky I, Scigalla P, Wieczorek L.
    Leukemia; 1990 Nov 01; 4(11):771-4. PubMed ID: 2232891
    [Abstract] [Full Text] [Related]

  • 9. Anaemia of chronic disease in rheumatoid arthritis: effect of the blunted response to erythropoietin and of interleukin 1 production by marrow macrophages.
    Smith MA, Knight SM, Maddison PJ, Smith JG.
    Ann Rheum Dis; 1992 Jun 01; 51(6):753-7. PubMed ID: 1616358
    [Abstract] [Full Text] [Related]

  • 10. Responsiveness of bone marrow erythropoietic stem cells (CFU-E and BFU-E) to recombinant human erythropoietin (rh-Ep) in vitro in aplastic anemia and myelodysplastic syndrome.
    Aoki I, Higashi K, Homori M, Chikazawa H, Ishikawa K.
    Am J Hematol; 1990 Sep 01; 35(1):6-12. PubMed ID: 2389770
    [Abstract] [Full Text] [Related]

  • 11. Effects of recombinant human stem cell factor (rh-SCF) on colony formation and long-term bone marrow cultures (LTBMC) in patients with myelodysplastic syndromes.
    Soligo D, Servida F, Cortelezzi A, Pedretti D, Uziel L, Morgutti M, Pogliani E, Lambertenghi Deliliers G.
    Eur J Haematol; 1994 Jan 01; 52(1):53-60. PubMed ID: 7507865
    [Abstract] [Full Text] [Related]

  • 12. In vivo effects of interleukin-11 and stem cell factor in combination with erythropoietin in the regulation of erythropoiesis.
    de Haan G, Dontje B, Engel C, Loeffler M, Nijhof W.
    Br J Haematol; 1995 Aug 01; 90(4):783-90. PubMed ID: 7545423
    [Abstract] [Full Text] [Related]

  • 13. Blast colony-forming cells in myelodysplastic syndrome: decreased potential to generate erythroid precursors.
    Backx B, Broeders L, Touw I, Löwenberg B.
    Leukemia; 1993 Jan 01; 7(1):75-9. PubMed ID: 8418382
    [Abstract] [Full Text] [Related]

  • 14. Age-related alterations in erythroid and granulopoietic progenitors in Diamond-Blackfan anaemia.
    Casadevall N, Croisille L, Auffray I, Tchernia G, Coulombel L.
    Br J Haematol; 1994 Jun 01; 87(2):369-75. PubMed ID: 7524624
    [Abstract] [Full Text] [Related]

  • 15. Responsiveness to stem cell factor (SCF) of peripheral blood colony-forming cells from patients with myelodysplastic syndromes (MDS).
    Masters GS, Baines P, Tang C, Bowen D, Burnett AK.
    Leuk Res; 1995 Aug 01; 19(8):561-6. PubMed ID: 7544850
    [Abstract] [Full Text] [Related]

  • 16. Stem cell factor improvement of proliferation and maintenance of hemopoietic progenitors in myelodysplastic syndromes.
    Piacibello W, Sanavio F, Bresso P, Severino A, Carlesso N, Pregno P, Stacchini A, Morelli S, Fubini L, Gallo E.
    Leukemia; 1994 Feb 01; 8(2):250-7. PubMed ID: 7508532
    [Abstract] [Full Text] [Related]

  • 17. Treatment of anemia in low risk myelodysplastic syndromes with granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin.
    Economopoulos T, Mellou S, Papageorgiou E, Pappa V, Kokkinou V, Stathopoulou E, Pappa M, Raptis S.
    Leukemia; 1999 Jul 01; 13(7):1009-12. PubMed ID: 10400415
    [Abstract] [Full Text] [Related]

  • 18. Stem cell factor (c-kit ligand) enhances the interleukin-9-dependent proliferation of human CD34+ and CD34+CD33-DR- cells.
    Lemoli RM, Fortuna A, Fogli M, Motta MR, Rizzi S, Benini C, Tura S.
    Exp Hematol; 1994 Aug 01; 22(9):919-23. PubMed ID: 7520394
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.